Akademik Veri Yönetim Sistemi
Medicine Science, cilt.12, sa.2, ss.393-397, 2023 (Hakemli Dergi)
This study aimed to evaluate the effects of low doses of atropine drops (0.05%, 0.025%, and 0.01% atropine sulfate) on spherical equivalent (SE) and axial length (AL) in children with myopia during the coronavirus disease 2019 pandemic. Participants were randomly classified into 4 groups: 0.05%, 0.025%, and 0.01% doses of atropine sulfate and placebo. Cycloplegic refraction diopters and AL were regularly calculated at 1, 3, 6, and 12 months after the onset of treatment. At the end of the first year, the difference in the mean SE values were −1.07±0.40 D, −0.71±0.66 D, −0.53±0.46 D, and −0.35±0.62 D in the placebo, 0.01% atropine, 0.025% atropine, and 0.05% atropine groups, respectively (p<0.001). During this period, the mean AL increase in the corresponding groups was 0.42±0.21, 0.37±0.24, 0.31±0.18, and 0.13±0.17 mm (p=0.02, p<0.001, p<0.001 in the 0.01%, 0.025%, and 0.05% atropine groups compared with the placebo group, respectively). Low-dose atropine drops may be the first choice of treatment for myopia progression owing to their ease of use and fewer side effects. All the investigated doses of atropine were statistically significantly efficient in slowing down myopia progression. However, our study revealed that 0.05% atropine best controlled both SE progression and AL elongation compared to 0.025% and 0.01% doses. We recommend initiating treatment with 0.01% atropine in children and switching to 0.025% or 0.05% atropine if adequate myopia progression control is not achieved.